Another Phase III Study Supports Avastin Expansion To Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Adding bevacizumab to chemo in first-line and maintenance therapy gives an undisclosed benefit in progression-free survival.
You may also be interested in...
Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT
The latest drug development news and highlights from our US FDA Performance Tracker.
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.
Roche is gearing up for a planned year-end submission of Avastin in advanced ovarian cancer in the EU after making a splash at the European Society for Medical Oncology meeting with updated data from its Phase III ICON7 study showing a progression-free survival benefit.